FDA — authorised 29 December 1993
- Application: NDA020272
- Marketing authorisation holder: JANSSEN PHARMS
- Status: supplemented
FDA authorised Risperdal on 29 December 1993
Yes. FDA authorised it on 29 December 1993; FDA authorised it on 10 June 1996; FDA authorised it on 2 April 2003.
JANSSEN PHARMS holds the US marketing authorisation.